#sitagliptin

CAS No : 654671-77-9| Product Name : Sitagliptin Phosphate Hydrate - API | Pharmaffiliates

Authored by  Zakaria A Almsherqi*

Mitochondria provide cellular energy through oxidative phosphorylation, but as an integral part of this process, superoxides and other reactive oxygen species (ROS) are also produced. When the balance between the production of free radicals and antioxidant capacity of the cardiac cells altered, oxidative stress is induced. Oxidative stress has been linked to the development of ischemic heart disease, atherosclerosis, congestive heart failure, ischemic-reperfusion injury, and vascular endothelial dysfunction. Although several clinical trials over the past decades employed different strategies of antioxidants supplementation, the results were generally negative in the setting of chronic preventative therapy.

Read more...FullText

For More Articles in Online Journal of Cardiovascular Research please click on https://irispublishers.com/ojcr/index.php

Development and Validation of an RP HPLC Method for Analysis of Sitagliptin

by Pradnya Lokhande ""Development and Validation of an RP-HPLC Method for Analysis of Sitagliptin""

Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-3 | Issue-6 , October 2019,

URL: https://www.ijtsrd.com/papers/ijtsrd29214.pdf

Paper URL: https://www.ijtsrd.com/chemistry/analytical-chemistry/29214/development-and-validation-of-an-rp-hplc-method-for-analysis-of-sitagliptin/pradnya-lokhande

ugc approved journals for management, mathematics journal, multidisciplinary journal

Epidemic spread of diabetes across the world, convenience of oral medication, and effectiveness of combination drugs despite studies linking risk of heart failures with the use of DPP-4 Inhibitors are poised to drive the global market for DPP-IV Inhibitors to reach US$10.6 billion by the year 2024.

Dipeptidyl Peptidase-IV (DPP4) inhibitors represent an important class of drugs in the treatment of Type 2 Diabetes mellitus. DPP-IV inhibitors, also called “gliptins”, inhibit the DiPeptidyl Peptidase IV (DPP-4) enzyme and enhance the action of its substrate, the incretin hormones, which then aid in increased insulin release and maintain appropriate glucose levels in the blood. Gliptins represent an attractive alternative to the first-line therapy of metformin for diabetes, especially in people who cannot tolerate biguanide metformin hydrochloride because of adverse gastrointestinal effects, and in whom metformin-only therapy is not effective. Sitagliptin (Januvia, Janumet), Vildagliptin (Galvus), Saxagliptin (Onglyza) and others such as Linagliptin, Alogliptin and Teneligliptin are the important drug classes in the DPP-IV inhibitors market.

Nevertheless, despite being well tolerated, most DPP-4 inhibitors are yet to be established with respect to durability of their effects. Certain long-term studies showed that usage of these drugs for over 4 years did not reduce the incidence of athrosclerotic events. This class of drugs may affect cardiac remodelling in patients of established heart failure, and may even increase the risk of new-onset heart failure. This CVD risk, corroborated by the recent FDA’s heart failure warning on the leading drug, Januvia, is likely to hamper the market growth.  However, the increasing demand for DPP-IV combination drugs would help the market to sustain in the ensuing years. Combinations like STEGLUJAN (ertugliflozin and sitagliptin), providing the benefits of both DPP-4 and SGLT-2 inhibitors is expected to result in a balanced therapy with an ideal tolerability and safety profile.

As stated by the new market research report on DPP-IV Inhibitors, the United States represents the largest market. Asia-Pacific ranks as the fastest growing market worldwide, with a CAGR of 9% over the analysis period, due to the huge population of diabetics. The growth in the region is backed by China and India with their huge type-2 diabetic and pre-diabetic population.

Major players in the market include AstraZeneca Plc., Boehringer Ingelheim GmbH, Eli Lilly and Company, Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation, Novartis AG, and Takeda Pharmaceutical Company Limited.

The research report titled "DPP-IV Inhibitors: A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, growth drivers, mergers and acquisitions, and other strategic industry activities of major companies worldwide. The report provides market size estimates and projections for geographic markets, such as the US, Canada, Japan, Europe (France, Germany, Italy, UK, Russia, and Rest of Europe), Asia-Pacific (China, India, South Korea, and Rest of Asia-Pacific), and Rest of World. Drug compound segments analyzed for the global market include Sitagliptin, Vildagliptin, Saxagliptin, and Others (including Alogliptin and Linagliptin). Drug segments analyzed for the US market include Sitagliptin, Saxagliptin, Linagliptin, and Alogliptin.  

For enquiries e-mail us at [email protected] or [email protected].

For cutting edge analyst reviews on top industries

  Application of On-Line NIR for Process Control during the Manufacture of Sitagliptin George Zhou*, Shane Grosser, Lei Sun, Gabriel Graffius, Ganeshwar Prasad, Aaron Moment, Angela Spartalis,Paul Fernandez, John Higgins, Busolo Wabuyele, and Cindy Starbuck Global Science, Technology and Commercialization, Merck Sharp & Dohme Corporation P.O. Box 2000, Rahway, New Jersey 07065, United States O…

Application of On-Line NIR for Process Control during the Manufacture of Sitagliptin

The transamination-chemistry-based process for sitagliptin is a through-process, which challenges the crystallization of the active pharmaceutical ingredient (API) in a batch stream composed of multiple components. Risk-assessment-based design of experiment (DoE) studies of particle size distribution (PSD) and crystallization showed that the final API PSD strongly depends on the seeding-point…

I risultati dello studio clinico LIRA-SWITCH, di confronto tra liraglutide (Victoza®, Novo Nordisk) e sitagliptin, entrambi in combinazione con metformina, presentato a ENDO 2016, congresso annuale della Società di endocrinologia americanatenutosi a Boston, dall’1 al 4 aprile scorso, hanno dimostrato che in adulti con diabete di tipo 2 passati dal trattamento con sitagliptin (100 mg) a…